The ImmunoCARE Study

Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

About the Study

The risks associated with COVID-19 infection are higher for immunocompromised individuals and people over 65 than the general public. ImmunoCARE is an innovative research project to study whether repeated at-home tests, on-demand telemedicine, and quick delivery of medication for those who test positive for COVID-19 can reduce COVID-19 severity in immunocompromised people.

ImmunoCARE is a joint research project from Scripps Research – a renowned biomedical research organization — and Cue Health, a leading health care technology company that develops portable diagnostic tests for at-home use.

Watch co-principal investigators Eric Topol, MD and Julia Moore Vogel, PhD to learn more about our motivations and vision.

Who Can Enroll

ImmunoCARE is available to individuals who are moderately to severely immunocompromised. Participants will provide documentation from a medical provider confirming their diagnosis.

Additional inclusion criteria includes:

Living in the United States
18 years or older
Vaccinated against COVID-19
Willing and able to participate in study interventions including:
- Use of a compatible smartphone, including camera and bluetooth
- Willing and able to share health insurance claims data from Medicaid, Medicare, or an Anthem plan
- Completing Surveys
- Use of Cue Health App and tests
- Use of MyDataHelps by Web or App
Immunocompromised, including
- Symptomatic HIV
- Graft versus host disease
- Immunoglobulin deficiency/Immunodeficiency
- Immunosuppressive therapy
- Leukemia
- Lymphoma (Hodgkin or non-Hodgkin)
- Metastatic Cancer
- Multiple Myeloma
- Solid organ malignancy
- Transplant, hematopoietic stem cell
- Transplant, solid organ
- 65 years or older

Living in the United States
18 years or older
Vaccinated against COVID-19
Willing and able to participate in study interventions including:
- Use of a compatible smartphone, including camera and bluetooth
- Willing and able to share health insurance claims data from Medicaid, Medicare, or an Anthem plan
- Completing Surveys
- Use of Cue Health App and tests
- Use of MyDataHelps by Web or App

Immunocompromised, including
- Symptomatic HIV
- Graft versus host disease
- Immunoglobulin deficiency/Immunodeficiency
- Immunosuppressive therapy
- Leukemia
- Lymphoma (Hodgkin or non-Hodgkin)
- Metastatic Cancer
- Multiple Myeloma
- Solid organ malignancy
- Transplant, hematopoietic stem cell
- Transplant, solid organ
- 65 years or older

What We Will Ask You to Do

ImmunoCARE will enroll 10,000 participants. Half of participants will test for COVID-19 and seek care as they normally would; the other half will receive at-home COVID-19 tests from Cue Health for themselves and others in their household. All participants will be asked to complete monthly surveys about COVID-19 exposure, infection, and hospitalization.

Our Thanks to You

As our thanks for your participation, all eligible participants will receive a series of Amazon gift cards as compensation for time throughout the study.

Join Today

Interested in helping advance research on COVID-19 outcomes for immunocompromised individuals? Click below to see if you are eligible to participate!

Let's Go

Questions? Reach out to us at ImmunoCARE@scripps.edu

Already joined the study? Log in at mydatahelps.org.